middle.news
LTR Pharma Doses First Patients in Pivotal SPONTAN Phase II Study
9:00am on Thursday 22nd of January, 2026 AEDT
•
Healthcare
Read Story
LTR Pharma Doses First Patients in Pivotal SPONTAN Phase II Study
9:00am on Thursday 22nd of January, 2026 AEDT
Key Points
First patients dosed in SPONTAN Phase II pharmacokinetic study
Study includes approximately 27 healthy males, half aged 65 or older
Initial data expected in Q2 2026 to support FDA regulatory submission
Focus on pharmacokinetics to inform dosing for older patients
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
LTR PHARMA (ASX:LTP)
OPEN ARTICLE